# Arbutus Biopharma Corp: overview ABUS · Nasdaq · CIK 1447028 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/abus.md) · [Financials](/companies/abus/financials.md) · [Filings](/companies/abus/filings.md) · [Insiders](/companies/abus/insiders.md) Latest reported revenue: [$1.0m](/filings/0001447028-26-000045.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:Revenues, accession 0001447028-26-000045). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.3](/filings/0001447028-25-000126.md) | [1.6 d](/filings/0001447028-26-000017.md) | [1.8](/filings/0001447028-26-000021.md) | [10.7](/filings/0001447028-26-000045.md) | [0.5](/filings/0001447028-25-000126.md) | [1.1 d](/filings/0001447028-26-000017.md) | [179](/filings/0001447028-26-000021.md) | [1.0](/filings/0001447028-26-000045.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1601.2%)](/filings/0001447028-25-000126.md) | [(885.2%) d](/filings/0001447028-26-000017.md) | [(1456.9%)](/filings/0001447028-26-000021.md) | [13.9%](/filings/0001447028-26-000045.md) | [(1636.9%)](/filings/0001447028-25-000126.md) | [(503.3%) d](/filings/0001447028-26-000017.md) | [94.3%](/filings/0001447028-26-000021.md) | [(588.2%)](/filings/0001447028-26-000045.md) | | Net margin | % | [(1472.5%)](/filings/0001447028-25-000126.md) | [(796.2%) d](/filings/0001447028-26-000017.md) | [(1390.4%)](/filings/0001447028-26-000045.md) | [23.5%](/filings/0001447028-26-000045.md) | [(1463.5%)](/filings/0001447028-25-000126.md) | [(357.4%) d](/filings/0001447028-26-000017.md) | [94.7%](/filings/0001447028-26-000045.md) | [(507.2%)](/filings/0001447028-26-000045.md) | | Diluted EPS | $ per share | [(0.10)](/filings/0001447028-25-000126.md) | not reported | [(0.13)](/filings/0001447028-26-000021.md) | [0.01](/filings/0001447028-26-000045.md) | [(0.04)](/filings/0001447028-25-000126.md) | not reported | [0.87](/filings/0001447028-26-000021.md) | [(0.03)](/filings/0001447028-26-000045.md) | | Free cash flow | $m | [(20.7) d](/filings/0001447028-25-000126.md) | [(10.4) d](/filings/0001447028-26-000017.md) | [(13.4)](/filings/0001447028-26-000021.md) | [(15.7) d](/filings/0001447028-26-000045.md) | [(5.8) d](/filings/0001447028-25-000126.md) | [(4.7) d](/filings/0001447028-26-000017.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.0](/filings/0001447028-23-000018.md) | [39.0](/filings/0001447028-24-000035.md) | [18.1](/filings/0001447028-25-000083.md) | [6.2](/filings/0001447028-26-000017.md) | [14.1](/filings/0001447028-26-000017.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(669.1%)](/filings/0001447028-23-000018.md) | [(167.8%)](/filings/0001447028-24-000035.md) | [(430.5%)](/filings/0001447028-25-000083.md) | [(1236.7%)](/filings/0001447028-26-000017.md) | [(271.0%)](/filings/0001447028-26-000017.md) | | Net margin | % | [(693.9%)](/filings/0001447028-23-000018.md) | [(178.0%)](/filings/0001447028-24-000035.md) | [(401.6%)](/filings/0001447028-25-000083.md) | [(1133.0%)](/filings/0001447028-26-000017.md) | [(237.9%)](/filings/0001447028-26-000017.md) | | Diluted EPS | $ per share | [(0.83)](/filings/0001447028-23-000018.md) | [(0.46)](/filings/0001447028-24-000035.md) | [(0.44)](/filings/0001447028-25-000083.md) | [(0.38)](/filings/0001447028-26-000017.md) | [(0.17)](/filings/0001447028-26-000017.md) | | Free cash flow | $m | [(68.3)](/filings/0001447028-23-000018.md) | [(35.9)](/filings/0001447028-24-000035.md) | [(86.9)](/filings/0001447028-25-000083.md) | [(65.0)](/filings/0001447028-26-000017.md) | [(39.6)](/filings/0001447028-26-000017.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/abus/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Two Seas Capital LP](/funds/1823138.md) | 2026-06-30 | $91.7m | 19,095,583 | | Added +538,040 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $85.0m | 17,698,305 | | Reduced −8,193,175 | | [Whitefort Capital Management, LP](/funds/1884931.md) | 2026-06-30 | $75.8m | 15,794,261 | | Added +863,376 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $66.1m | 13,766,071 | | Added +799,125 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $37.8m | 7,869,179 | | Added +1,526,669 | | [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $36.2m | 7,532,937 | | Added +906,548 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $33.7m | 7,010,679 | | Added +321,768 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $20.2m | 4,207,914 | | Reduced −108,181 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $19.8m | 4,117,691 | | Added +345,885 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $16.8m | 3,506,802 | | Added +2,406,368 | ## Recent filings [All 1,015 filings](/companies/abus/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 07:31 ET | [8-K](/filings/0001171843-26-006753.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-006753 | | 2026-08-21 | 07:53 ET | [8-K](/filings/0001104659-26-099390.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-099390 | | 2026-08-12 | 07:31 ET | [10-Q](/filings/0001447028-26-000045.md) | Quarterly report, period 2026-06-30 | 0001447028-26-000045 | | 2026-08-12 | 07:31 ET | [8-K](/filings/0001171843-26-005442.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005442 | | 2026-07-16 | 07:31 ET | [8-K](/filings/0001171843-26-004708.md) | 1.02 Termination of a material agreement; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-004708 | | 2026-05-27 | 16:01 ET | [8-K](/filings/0001447028-26-000024.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001447028-26-000024 | | 2026-05-13 | 07:31 ET | [10-Q](/filings/0001447028-26-000021.md) | Quarterly report, period 2026-03-31 | 0001447028-26-000021 | | 2026-05-13 | 07:31 ET | [8-K](/filings/0001171843-26-003346.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-003346 | | 2026-04-28 | 17:54 ET | [SCHEDULE 13D/A](/filings/0000921895-26-001101.md) | Ownership report, active investor, amended | 0000921895-26-001101 | | 2026-04-15 | 07:31 ET | [8-K](/filings/0001171843-26-002458.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-002458 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001447028-26-000017.md), filed Mar 23, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f15c71b7-7a27-4b0d-be89-e7a057ead393) ## About the filer - CIK: 1447028 - Tickers: ABUS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:27 ET. No prices; not investment advice.